Patents by Inventor Fred Gluck
Fred Gluck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210284721Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: October 22, 2020Publication date: September 16, 2021Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Patent number: 10875913Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: August 23, 2018Date of Patent: December 29, 2020Assignee: CytomX Therapeutics, Inc.Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Publication number: 20190119370Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: August 23, 2018Publication date: April 25, 2019Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Patent number: 10118961Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: August 24, 2016Date of Patent: November 6, 2018Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Patent number: 10059762Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: April 28, 2016Date of Patent: August 28, 2018Assignee: CytomX Therapeutics, Inc.Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Publication number: 20170081397Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: August 24, 2016Publication date: March 23, 2017Inventors: Nancy E. Stagliano, James William West, Kathryn Kamath, Paul Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Patent number: 9453078Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: September 26, 2013Date of Patent: September 27, 2016Assignee: CYTOMX THERAPEUTICS, INC.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
-
Publication number: 20160228546Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: April 28, 2016Publication date: August 11, 2016Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Publication number: 20140024810Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: September 26, 2013Publication date: January 23, 2014Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
-
Publication number: 20130309230Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: March 4, 2013Publication date: November 21, 2013Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
-
Patent number: 8513390Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: April 25, 2012Date of Patent: August 20, 2013Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty